A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab. The main questions it aims to answer are: Is obinutuzumab non-inferior to glucocorticoids at inducing remission? Does obinutuzumab provide superiority in terms of relapse-free survival after 52 weeks? What medical problems do participants have when receiving obinutuzumab? Researchers will compare drug obinutuzumab to glucocorticoids and aim to phenotype participants with minimal change disease. Participants will: Take the drug obinutuzumab (2 doses) or glucocorticoids Visit the clinic for 8 visits over a period of 52 weeks, plus additional controls when disease relapses occur

NCT Number	NCT07710157
Lead Sponsor	Medical University Innsbruck Collaborators: Henri Mondor University Hospital, Centre Hospitalier Universitaire de Nice, Medical University of Graz, WiGeV Klinik Ottakring, Universitätsklinikum Hamburg-Eppendorf
Conditions	Minimal Change Disease (MCD)
Enrollment	48 participants
Start Date	2026-07-13
Primary Completion	2028-06-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-21